Home > Cardiology > AHA 2021 > Heart Failure > Therapeutic approaches in heart failure with diabetes

Therapeutic approaches in heart failure with diabetes

Presented By
Prof. Lynne Stevenson, Vanderbilt University Medical Center, USA
Conference
AHA 2021
The new therapeutic options for patients with heart failure (HF) offer physicians a growing number of choices in finding the right integrated approach in the treatment of HF patients with diabetes mellitus. Key considerations, according to Prof. Lynne Stevenson (Vanderbilt University Medical Center, TN, USA) are the robustness or frailty of the patient, the stage of disease, and the patient’s financial resources and accessibility to healthcare facilities [1]. HFrEF The 3 fundamental therapies for patients with HF with reduced ejection fraction (HFrEF) are angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and β-blockers. The first choice of therapy depends on heart rate, blood pressure, and renal function. “For example, in patients with an increased heart rate, β-blockers would be the first therapy of choice. If we want to expand from our fundamental therapies, an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on